Hormonal
Semaglutide 2.4 mg/week significantly reduces major adverse cardiovascular events (MACE) in overweight or obese adults with preexisting cardiovascular disease but without diabetes.
If you are overweight or obese and have existing heart disease but no diabetes, ask your doctor about semaglutide 2.4 mg/week. It is the first obesity medication proven to lower the risk of heart attacks, strokes, and cardiovascular death. The treatment involves a weekly injection, starting at a low dose to minimize stomach issues, and has been shown to significantly improve cardiovascular outcomes over standard care alone.
In conclusion, semaglutide is the first anti-obesity agent shown to decrease CV events in overweight/obese subjects with CV disease without diabetes.
Why this rating
Based on the SELECT trial, a large (n=17,604), multinational, randomized, placebo-controlled, double-blind megatrial.
Source
Semaglutide: The First Anti-Obesity Agent Shown to Decrease Cardiovascular Events
Nasser Mikhail et al. · Annals of Cardiovascular Diseases · 2024
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →